Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Voecklabruck – page 6

95 clinical trials in Voecklabruck, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Voecklabruck at a glance
95
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

95 trials in Voecklabruck

Open in trial search

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

B-cell lymphoma+2

Not recruiting

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:GWT-Tud GmbH

Study on the Safety of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Astrazeneca AB

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Oncology Inc.

Polycythaemia vera

Not recruiting

Study Comparing Givinostat and Hydroxyurea for Patients with High-Risk Polycythemia Vera

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carbasalate Calcium
  • Sponsor:Italfarmaco S.p.A.

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitat Dresden

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Voecklabruck

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on HER2-negative breast cancer treatments, evaluating novel therapeutic approaches for improving patient outcomes.

  • Targeted Therapies
  • Adjuvant Treatments
  • Disease-Free Survival Studies

Research emphasizes personalized treatment strategies for different breast cancer subtypes.

02 Hormone Receptor Studies

Comprehensive research on hormone receptor-positive breast cancers, investigating extended therapy options and combination treatments.

  • Endocrine Therapy
  • Extended Treatment Protocols
  • Recurrence Prevention

Studies aim to enhance long-term treatment effectiveness for early-stage breast cancer.

03 Innovative Drug Development

Exploration of novel therapeutic agents including targeted antibody-drug conjugates and specialized inhibitors.

  • New Drug Applications
  • Treatment Combinations
  • Risk Reduction Strategies

Focus on developing more effective and personalized treatment options.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.